Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 35,041	$ 51,059
Prepaid expenses and other	1,168	1,791
Total current assets	37,171	57,840
Equipment, net	2,882	3,002
Deposits and other	1,613	888
Total assets	41,666	61,730
Current liabilities:
Accrued compensation and related benefits	773	1,901
Accrued clinical trial related costs	1,160	1,276
Accrued expenses	723	461
Total current liabilities	12,837	15,475
Other long-term liabilities	220	0
Stockholders’ equity:
Preferred stock, at stated value; 10,000,000 shares authorized, and no shares issued and outstanding at December 31, 2019 and 2018	0	0
Common stock, $0.001 par value; 300,000,000 shares authorized; 159,791,585 and 144,292,739 shares issued and outstanding at December 31, 2019 and 2018, respectively	160	144
Additional paid-in capital	440,735	416,014
Accumulated deficit	(417,624)	(373,042)
Total stockholders’ equity	23,271	43,116
Total liabilities and stockholders’ equity	41,666	61,730
Consolidated entity, excluding related party
Current assets:
Accounts receivable	17	262
Current liabilities:
Accounts payable	9,048	9,163
Healios
Current assets:
Accounts receivable	945	1,108
Unbilled accounts receivable from Healios	0	3,620
Current liabilities:
Accounts payable	1,068	0
Deposit from Healios	0	2,000
Deferred revenue - Healios	65	674
Advance from Healios	$ 5,338	$ 3,139